SNS Research Group has published its flagship report, "Dermatological Drugs Market: 2025–2035"

PITTSBURGH - EntSun -- SNS Research positions dermatological drugs as the largest and most strategically important segment within the broader dermatology market, with global spending projected to reach $52.8 billion by 2025. Growth is driven by rising prevalence of chronic inflammatory skin diseases, persistent unmet medical need, and rapid innovation across biologics, targeted oral therapies, advanced topicals, and next-generation delivery technologies.

The analysis captures a market undergoing structural transformation. Advanced biologics now represent the primary growth engine, redefining standards of care in psoriasis, atopic dermatitis, alopecia areata, and other immune-mediated skin disorders. IL-23 and IL-17 inhibitors are setting new benchmarks for long-term disease control, while TYK2 inhibitors are reshaping competition by combining targeted efficacy with oral convenience. Parallel innovation in topical therapies—including JAK and PDE4 inhibitors—is expanding treatment optionality and improving patient adherence.

More on EntSun News

• The Best And Worst Of Entertainment In 2025 Revealed
• Robert DeMaio, Phinge Founder & CEO, Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
• Indie Film Marries Arthouse Aesthetics to Fantasy While Tackling Themes of Humanity and the Ecology
• 2025: A Turning Point for Human Rights. CCHR Demands End to Coercive Psychiatry
• The 22% Tax Reality: Finland's New Gambling Law Creates a "Fiscal Trap" for Grey Market Casino Players

The report provides full market sizing and forecasts from 2025 to 2035, segmented across:

• Seven therapeutic categories
• Three routes of administration
• OTC versus prescription drugs
• Four distribution channels
• Three major drug classes, including biologics, small molecules, and gene & emerging therapies
• Twenty-six country markets across five global regions

Beyond quantitative forecasts, the report delivers deep coverage of:

• Dermatological disorders and application areas
• Drug delivery technologies and formulation innovation
• Competitive dynamics, including patent expirations and biosimilar entry
• Late-stage and emerging clinical pipeline trends
• Industry roadmap, value chain structure, and ecosystem evolution
• Profiles and strategies of 83 leading dermatology and biopharmaceutical companies

The findings highlight intensifying competitive pressure driven by biosimilars, particularly following the 2025 entry of multiple ustekinumab biosimilars, forcing originators to deploy aggressive lifecycle, pricing, and access strategies. Strategic acquisitions and alliances continue to reshape the landscape, reinforcing a broad industry pivot toward precision immunology and differentiated mechanisms.

More on EntSun News

• Streaming Industry Consultant Marc Rashba Joins BayView and DotStudioPro to Bolster Content Reach
• Holiday Comedy A Boyfriend For Christmas Wins Over Audiences with Laughs, Heart — and a Twist
• Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes
• TIA LYNN — a new direction, a higher level. 2026 it's up
• Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion

The full "Dermatological Drugs 2025 Market" report, is available at: https://www.snsresearch.com/dermatological-drugs-market.html​

The report is designed for pharmaceutical executives, strategy and business development teams, investors, and policymakers requiring high-fidelity market intelligence to support decision-making in dermatology.
An accompanying Excel data suite provides all underlying quantitative forecasts and a 2025 clinical pipeline dataset, enabling direct integration into internal models and strategy workflows.

About SNS Research Group LLC
SNS Research Group LLC is a B2B healthcare and pharmaceutical intelligence firm delivering high-signal market reports, clinical pipeline datasets, and executive-grade analysis across specialty therapeutics. The firm focuses on markets where biology, competition, and commercial strategy intersect.